<DOC>
	<DOCNO>NCT00855439</DOCNO>
	<brief_summary>This study look whether medication exenatide improve sign symptom diabetic peripheral neuropathy people type 2 diabetes mild moderate diabetic peripheral neuropathy .</brief_summary>
	<brief_title>Evaluation Exenatide Patients With Diabetic Neuropathy</brief_title>
	<detailed_description>This study look effect medication exenatide peripheral neuropathy people type 2 diabetes . Exenatide ( trade name , BYETTA® ) injectable medication use people type 2 diabetes control blood sugar . Peripheral neuropathy complication diabetes cause symptom numbness , tingle burn sensation foot hand . Controlling blood sugar level type 2 diabetes think prevent , delay improve damage nerve fiber cause peripheral neuropathy . There also evidence exenatide may additional beneficial effect peripheral nerve , beyond benefit blood sugar control alone . In study , half participant take exenatide injection twice daily half take insulin glargine ( Lantus® ) injection daily . Both group expect similar improvement blood sugar control . This study show whether exenatide beneficial effect neuropathy beyond benefit well blood sugar control alone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes treat one oral agent Persistent fast glucose &gt; 140 mg/dl HbA1c &gt; 7 % Stable maximally effective dos one oral agent 3 month Presence diabetic peripheral neuropathy Age 18 70 year No risk factor cause neuropathy Willingness capacity sign Institutional Review Board approve consent form cooperate medical procedure study duration Nursing mother pregnant woman A history previous kidney , pancreas cardiac transplantation A past history neuropathy ( independent diabetes ) disease know associate neuropathy ( e.g. , hepatitis C , end stage renal disease , lupus ) Amputation part either low extremity reason traumatic loss part either low extremity congenital absence severe deformity lower extremity HbA1c &gt; 10 % Participation experimental medication trial within 3 month start study . Undergoing therapy malignant disease basal squamous cell carcinoma Requiring longterm glucocorticoid therapy Inability unwillingness comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Glucose</keyword>
	<keyword>Control</keyword>
	<keyword>Peripheral</keyword>
	<keyword>Autonomic</keyword>
</DOC>